Johnson & Johnson (NYSE: JNJ) reported Q1 EPS of $1.83, $0.06 better than the analyst estimate of $1.77. Revenue for the quarter came in at $17.8 billion versus the consensus estimate of $18.03 billion.

Johnson & Johnson said the Actelion acquisition remains on track to close in the second quarter.

"Johnson & Johnson's first-quarter results are in line with our expectations and we are confident we will achieve the full-year financial guidance we established at the beginning of the year," said Alex Gorsky, Chairman and Chief Executive Officer. "The pending acquisition of Actelion demonstrates our ongoing commitment to bringing innovation to patients with significant unmet needs, and provides a unique opportunity for us to expand our portfolio with leading, differentiated in-market medicines and promising late-stage products. We look forward to the associates from Actelion joining the Johnson & Johnson Family of Companies."

GUIDANCE:

Johnson & Johnson sees FY2017 EPS of $7.00-$7.15, versus the consensus of $7.05.

For earnings history and earnings-related data on Johnson & Johnson (JNJ) click here.